Canada’s Healthcare Industry After COVID-19: Legal, Medical and Business Perspectives (Videos)

July 15, 2020

In light of the rapid evolution of healthcare in response to the COVID-19 pandemic, Mario Nigro, a partner in our Mergers & Acquisitions and Private Equity & Venture Capital Groups, recently hosted a virtual sit-down discussion with leaders and experts from inside and outside the firm.

Sharing expertise from legal, medical and business perspectives, the panel canvassed the following topics (click on each heading to view the corresponding discussion):

The Role of Technology in Healthcare and Preparing for the Future

A conversation with Dr. Sandy Buchman, President, Canadian Medical Association.

  • What changes have you noticed in Canadian healthcare since the onset of the COVID-19 pandemic? What role has technology played? 00:46
  • Will there be a greater focus on virtual care and technology in the delivery of healthcare services? 05:07
  • What changes are expected with respect to the quality and delivery of healthcare services to seniors? 07:24
  • What steps has Canada taken with respect to a possible second wave as we begin to re-open our economy? 12:58 

Regulatory Considerations and Healthcare Going Forward

A conversation with Sara Zborovski, Partner, Corporate Group, focusing on Life Sciences & Healthcare, Stikeman Elliott.

  • How has Health Canada handled the regulation of COVID-related drugs, products and medical devices amid the pandemic? 00:57
  • What additional sales and distribution channels have opened up in the healthcare industry during the pandemic and how will the industry be impacted in the short or long term? 08:31
  • How will new market entrants remain relevant once the pandemic has passed? 12:40
  • Is the speed and pace of regulatory approvals for drugs, products and medical devices temporary? Will we see a more responsive and nimble regulator post-COVID? 15:50

Competition and Foreign Investment Considerations in Canadian Healthcare

A conversation with Michael Laskey, Partner, Competition & Foreign Investment, Stikeman Elliott.

  • Will there be challenges and limits on foreign investment in the Canadian healthcare industry in a post-COVID world? 00:32
  • If foreign investment is going to be limited to some degree, what considerations will form part of the regulator's review? Is foreign investment in the healthcare space likely to attract higher scrutiny from a national security perspective? 05:42
  • Will the Canadian Competition Bureau apply enhanced scrutiny on both foreign and domestic investment in the healthcare sector post-COVID? What does this mean for healthcare transactions? 11:09

DISCLAIMER: This publication is intended to convey general information about legal issues and developments as of the indicated date. It does not constitute legal advice and must not be treated or relied on as such. Please read our full disclaimer at

Stay in Touch with Knowledge Hub